Bio-pharma firm subscribes to bank structured deposit product

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. has entered into an agreement with the Bank of China to subscribe to a structured deposit product. The investment amount totals RMB180 million, sourced from the company's temporary idle proceeds from its public issuance of A shares. The deposit product is principal-guaranteed with a floating return, categorized as low-risk, and will last for 88 days. The expected annualized return rate ranges from 0.4500% to 1.6000%, determined by the central parity price of EUR/USD. The company believes this investment enhances the overall capital gain of the group while safeguarding capital and ensuring liquidity. The board of directors confirms the agreement is on normal commercial terms and in the best interest of the company and its shareholders. This transaction is disclosable but exempt from shareholder approval under the Listing Rules.